Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 19% of the time (731 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: adalzheimertolerabilitykidneydementia
  Phrases that lowered it: the aimscreeningaim ofmaleevaluate the
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Blinding: quadruple (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Phase: 2 (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Collaborators: 2 (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 50 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Sponsor's past trials: 1 (lowers risk) · Sponsor's track record
• Maximum age: 89 (lowers risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu) NCT02727699 · started 2017 · scored riskier than 81% of active trials completed
• Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease NCT03533257 · started 2018 · scored riskier than 60% of active trials completed
• Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease NCT02925650 · started 2017 · scored riskier than 97% of active trials completed
• A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease NCT05478031 · started 2022 · scored riskier than 70% of active trials terminated
• Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease NCT01009255 · started 2009 · scored riskier than 50% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.